RE: Late Trade27 Aug 2025 19:02
2 Aug 2024 07:00
Investment of £1.56m from new investors
· Company was not actively seeking further funding, already funded to *****Q1 2025*****
The additional funding of £1.44m (net of expenses) will enable the Company to continue to support the roll-out of AxisBiotix-Ps, the commercialisation of the acne treatment and the potential payment of the Dermatonics deferred consideration in 2025, as well as general working capital. It will also strengthen the Company's balance sheet to support the potential acquisition, removing the need for the proposal to borrow an additional £0.5m under any acquisition financing facilities.
Given the cash burn etc, how could none of you not foreseen what the spiking in price was for before June y/e unaudited?
Does the supe3rdrug spin of bringing it forward sound more like an emergency cash facilitation?